JPS62123119A - Miotic inhibitor in ophthalmic operation - Google Patents
Miotic inhibitor in ophthalmic operationInfo
- Publication number
- JPS62123119A JPS62123119A JP26309285A JP26309285A JPS62123119A JP S62123119 A JPS62123119 A JP S62123119A JP 26309285 A JP26309285 A JP 26309285A JP 26309285 A JP26309285 A JP 26309285A JP S62123119 A JPS62123119 A JP S62123119A
- Authority
- JP
- Japan
- Prior art keywords
- miosis
- acetylsalicylic acid
- inhibitor
- surgery
- miotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔技術分野〕
本発明は、アセチルサリチル酸、その誘導体およびそれ
らの生理学的に許容される塩から選ばれる少なくとも一
種を有効成分とする眼手術時の縮瞳抑制剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Technical Field] The present invention relates to an agent for suppressing miosis during eye surgery, which contains at least one selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof as an active ingredient.
アセチルサリチル酸は、鎮痛薬、解熱薬および抗リウマ
チ薬として古くから使用され、近年非ステロイド系抗炎
症薬として、リウマチ、関節炎、神経痛、筋肉痛などの
治療に広く用いられているが、現在までアセチルサリチ
ル酸を眼手術時の縮瞳抑制剤として使用することは知ら
れていない。Acetylsalicylic acid has long been used as an analgesic, antipyretic, and antirheumatic drug, and in recent years it has been widely used as a nonsteroidal anti-inflammatory drug to treat rheumatism, arthritis, neuralgia, muscle pain, etc. Salicylic acid is not known to be used as a miosis inhibitor during eye surgery.
眼手術時におけるｗ１１１！は手術の妨げになる厄介な
問題である。w111 during eye surgery! is a troublesome problem that hinders surgery.
現在、眼手術時の縮瞳防止にはインドメタンン点眼剤が
使用されているが、期待する程度の充分な縮瞳抑制効果
が得られないことが多い。Currently, indomethane eye drops are used to prevent miosis during eye surgery, but in many cases, the expected miosis-suppressing effect is not obtained.
本発明の目的は、縮瞳抑制作用が強力で、かつ確実なる
縮瞳抑制効果が得られ、しかも副作用の少ない眼手術時
の縮瞳抑制剤を堤供することにある。An object of the present invention is to provide a miosis inhibitor for use in eye surgery that has a strong and reliable miosis inhibiting effect and has few side effects.
本発明者らは、上記の目的を解決するために種々研究を
重ねた結果、アセチルサリチル酸、その誘導体およびそ
れらの生理学的に許容される塩が強力な縮瞳抑制作用を
存することを見出すとともに、その安全性を確認するこ
とによって本発明を完成した。As a result of various studies aimed at solving the above object, the present inventors discovered that acetylsalicylic acid, its derivatives, and their physiologically acceptable salts have a strong miosis-inhibiting effect, and The present invention was completed by confirming its safety.
即ち、本発明は、アセチルサリチル酸、その誘導体およ
びそれらの生理学的に許容される塩（以下、これらを総
称して本発明有効成分ともいう）から選ばれる少なくと
も一種を有効成分とする眼手術時の縮瞳抑制剤に関する
。That is, the present invention provides a method for use in eye surgery that contains at least one type of active ingredient selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof (hereinafter collectively referred to as the active ingredient of the present invention). Concerning miotic inhibitors.
本発明にて使用されるアセチルサリチル酸又はその誘導
体の塩としては、有機塩基塩、アルカリ。The salts of acetylsalicylic acid or its derivatives used in the present invention include organic base salts and alkalis.
金属塩（ナトリウム塩等）、アルカリ土類金属塩（カル
シウム塩等）が例示される。とりわけ塩基性アミノ酸（
たとえば、アルギニン、リジン）との塩が好ましい。特
に好ましくは、アセチルサリチル酸のリジン塩（特に、
アセチルサリチル酸−ＤＬ−リジン塩）である。かかる
塩は、水溶性となり、眼部局所投与や静脈内投与が可能
であり、眼における恣染症および緑内障の恐れはなく、
また、内服薬で知られているような胃腸障害を惹起する
ことがない。Examples include metal salts (sodium salts, etc.) and alkaline earth metal salts (calcium salts, etc.). Especially basic amino acids (
For example, salts with arginine, lysine) are preferred. Particularly preferably, the lysine salt of acetylsalicylic acid (especially
acetylsalicylic acid-DL-lysine salt). Such salts are water-soluble and can be administered locally or intravenously to the eye, and there is no risk of ocular staining or glaucoma.
In addition, it does not cause gastrointestinal disorders, which are known to occur with oral medications.
アセチルサリチル酸の誘導体としては、眼手術時の縮瞳
抑制を有するものであれば特に制限はなく、特にそれ自
体または塩の態様として水溶性のものが好ましい。There are no particular limitations on the derivative of acetylsalicylic acid as long as it suppresses miosis during eye surgery, and water-soluble ones are particularly preferred, either by themselves or in the form of a salt.
なお、アセチルサリチル酸−ＤＬ−リジン塩の製造法と
しては、特開昭５６−ＩＱＬＩＱの明細占にその記載が
ある。The method for producing acetylsalicylic acid-DL-lysine salt is described in the specification of JP-A-56-IQLIQ.
本発明有効成分は、インドメタシンと併用することによ
って更に優れた眼手術時の縮瞳抑制作用を示す。その際
インドメタシンは眼局所に投与され、従来の投与量と同
程度の量を投与すればよい。When the active ingredient of the present invention is used in combination with indomethacin, it exhibits even more excellent miosis suppressing action during eye surgery. At that time, indomethacin is administered locally to the eye, and the dose may be comparable to the conventional dose.
本発明有効成分は、通常、眼手術の数分〜数時間前に、
経口または経静脈あるいは眼局所に投与される。投与量
は、体重、年令等に応じて適宜選択すればよく、通常ア
セチルサリチル酸として５〜５０ｍｇ／Ｋｇ程度である
。The active ingredient of the present invention is usually administered several minutes to several hours before eye surgery.
It is administered orally, intravenously, or locally into the eye. The dosage may be appropriately selected depending on body weight, age, etc., and is usually about 5 to 50 mg/Kg of acetylsalicylic acid.
本発明の眼手術時の縮瞳抑制剤は、後記臨床例で明らか
なように、眼手術時の縮瞳に対して高い抑制作用を有し
ており、眼手術時の縮瞳抑制剤として極めて優れた効果
を有する。また、インドメタシンと併用することによっ
てさらに価れた当該作用、効果が得られる。The miotic inhibitor for eye surgery of the present invention has a high inhibitory effect on miosis during eye surgery, as is clear from the clinical examples described later, and is extremely effective as a miosis inhibitor for eye surgery. Has excellent effects. Further, by using it in combination with indomethacin, further enhanced effects and effects can be obtained.
アセチルサリチル酸−ＤＬ−リジン塩（ＡＳＡ）の術前
、静脈投与による白内障嚢外摘出術時の縮瞳抑制効果に
つき検討した。The effect of preoperative intravenous administration of acetylsalicylic acid-DL-lysine salt (ASA) on miosis suppression during extracapsular cataract extraction was investigated.
方法：術前の散瞳はミドリンＰ（登録商標）、ネオシネ
ジン（登録商標）点眼により行い、症例は次の５群に分
けられた。尚、各群２０眼とした。Method: Preoperative mydriasis was performed using Midrin P (registered trademark) and Neosynegin (registered trademark) eye drops, and the cases were divided into the following 5 groups. There were 20 eyes in each group.
１群＝０．５％インドメタシン点眼液（ＩＤ）点眼（術
前２時間、１時間、３０分、３回）■群：ＡＳＡ９００
■静注（術前約３０分、１回）■群： Ａ Ｓ Ａ
１８００■静注（術前約３０分、１回）■群：０．５％
ＩＤ点眼液の点眼とＡ Ｓ Ａ ９００ｍｇ静注（術
前約３０分、１回）併用
Ｖ群＝０．５％ＩＤ点眼液の点眼とＡ Ｓ Ａ １８０
０ｍｇ静注（術前１時間、１回）併用。Group 1 = 0.5% indomethacin ophthalmic solution (ID) eye drops (2 hours before surgery, 1 hour, 30 minutes, 3 times) Group: ASA900
■Intravenous injection (approximately 30 minutes before surgery, once) ■Group: A S A
1800 ■ Intravenous injection (approximately 30 minutes before surgery, once) ■ Group: 0.5%
ID ophthalmic solution eye drops and ASA 900mg intravenous injection (approximately 30 minutes before surgery, once)Group V = 0.5% ID ophthalmic solution eye drops and ASA 180
Combined with 0mg intravenous injection (once 1 hour before surgery).
術前・術後の瞳孔径を顕微鏡下でカリバーにて計測し、
各群における術前・術後の瞳孔径の変化率を次式
％式％）
（式中、Ｐｏは術前の瞳孔径を、Ｐ、は術後の瞳孔径を
示す）
によって求め、その結果を第１１１ｆｆｉに示した。Measure the pupil diameter before and after surgery with a caliber under a microscope.
The rate of change in pupil diameter before and after surgery in each group was calculated using the following formula (%) (where Po is the preoperative pupil diameter and P is the postoperative pupil diameter). was shown in the 111th ffi.
結果と結論＝ＩＤ点眼のみとＡＳＡ静圧のみの群は共に
同等の縮瞳抑制効果があり、］Ｄ点眼とＡＳＡ静注を併
用した群ではより強い縮瞳抑制効果が得られ、白内障嚢
外摘出術におけるアセチルサリチル酸＝ＤＬ−リジン塩
静注剤の術前投与の有用性が示された。金側に副作用は
認められなかった。Results and Conclusions: ID drops only and ASA static pressure only have the same miosis suppressing effect, and the group using D drops and ASA intravenous injection has a stronger miosis suppressing effect, and cataract extracapsular The usefulness of preoperative administration of intravenous acetylsalicylic acid = DL-lysine salt in resection surgery was demonstrated. No side effects were observed on the gold side.
第１図は、本発明製剤を使用時の術前・術後の瞳孔径変
化率を示すためのグラフである。
：Ｑ−二〜已′
第り図
手続補正書（自発）
昭和６１年２月１９日
１、事件の表示
昭和６０年特許願第２６３０９２号
２、発明の名称
眼手術時の縮瞳抑制剤
３、補正をする者
事件との関係 特許出願人
氏名（名称） 株式会社 ミドリ十字
４、代理人■５４１
住所 大阪市東区平野町４丁目５３番地３ニューライフ
平野町４０６号
電話（０６） ２２７−１１５６
明細書の１発明の詳細な説明」の欄
６、補正の内容
（１）明細書第５真、第１１行の「１０００ｍｇＪをｒ
９００ｍｇＪに訂正する。
手３売′主甫正書く自発）
昭和６１年９月１８日
昭和６０年特許願第２６３０９２号
２、発明の名称
眼手術時の縮瞳抑制剤
３、補正をする者
事件との関係 特許出願人
氏名（名称） 株式会社 ミドリ十字
４、代理人■５４１
住所 大阪市東区平野町４丁目５３番地３ニューライフ
平野町４０６号
狙（０６） ２２７−１１５６
明細書全文および図面
゛）・、。
ジ
明細書（訂正）
１、発明の名称
眼手術時の縮瞳抑制剤
２、特許請求の範囲
アセチルサリチル酸、その誘導体およびそれらの生理学
的に許容される塩から選ばれる少なくとも一種を有効成
分とする眼手術時の縮瞳抑制剤。
３、発明の詳細な説明
〔技術分野〕
本発明は、アセチルサリチル酸、その誘導体およびそれ
らの生理学的に許容される塩から選ばれる少なくとも一
種を有効成分とする眼手術時の縮瞳抑制剤に関する。
〔発明の背景〕
アセチルサリチル酸は、鎮痛薬、解熱薬および抗リウマ
チ薬として古くから使用され、近年非ステロイド系抗炎
症薬として、リウマチ、関節炎、神経痛、筋肉痛などの
治療に広く用いられているが、現在までアセチルサリチ
ル酸を眼手術時の縮瞳抑制剤として使用することは知ら
れていない。
眼手４＋ｊ時における縮瞳は手術の妨げになる厄介な問
題である。
最近、眼手術時の縮瞳防止にインドメタシン点眼剤が開
発され使用されているが、より効果が認められる薬剤の
開発が望まれている。
〔発明が解決しようとする問題点〕
本発明の目的は、縮瞳抑制作用が強力で、かつ確実なる
縮瞳抑制効果が得られ、しかも副作用の少ない眼手術時
の縮瞳抑制剤を提供することにある。
〔問題点を解決するための手段〕
本発明者らは、上記の目的を解決するために種々研究を
重ねた結果、アセチルサリチル酸、その誘導体およびそ
れらの生理学的に許容される塩が強力な縮瞳抑制作用を
有することを見出すとともに、その安全性を確認するこ
とによって本発明を完成した。
即ち、本発明は、アセチルサリチル酸、その誘導体およ
びそれらの生理学的に許容される塩（以下、これらを総
称して本発明有効成分ともいう）から選ばれる少なくと
も一種を有効成分とする眼手術時の縮瞳抑制剤に関する
。
本発明にて使用されるアセチルサリチル酸又はその５Ａ
感体の塩としては、有機塩基塩、アルカリ金属塩（す
Ｉ−ＩＪウム塩等）、アルカリ土類金属塩（カルシウム
塩等）が例示される。とりわけ塩基性アミノ酸（たとえ
ば、アルギニン、リジン）との塩が好ましい。特に好ま
しくは、アセチルサリチル酸のリジン塩（特に、アセチ
ルサリチルＨ＝Ｄ Ｌ−リジン塩）である。かかる塩は
、水ｌ容性となり、眼部局所投与や静脈内投与が可能で
あり、眼における感染症の増悪やステロイド緑内障の恐
れはなく、また、内服薬で知られているような胃腸障害
を惹起することがない。
アセチルサリチル酸の誘導体としては、眼手術時の縮瞳
抑制を有するものであれば特に制限はなく、特にそれ自
体または塩の態様として水溶性のものが好ましい。
なお、アセチルサリチル酸−ＤＬ−リジン塩の製造法と
しては、特開昭５６−１０１１０の明細占にその記載が
ある。
本発明有効成分は、インドメタシン点眼剤と併用するこ
とによって更に優れた眼手術時の縮瞳抑制作用を示す。
本発明有効成分は、通常、眼手術の数分〜数時間前に、
経口または経静脈あるいは眼局所に投与される。投与量
は、体重、年令等に応して適宜選択すればよく、通常ア
セチルサリチル酸として５〜５０ｍｇ／ｋｇ程度である
。
〔発明の作用・効果〕
本発明の眼手術時の縮瞳抑制剤は、後記臨床例で明らか
なように、眼手術時の縮瞳に対して高い抑制作用を有し
ており、眼手術時の縮瞳抑制剤として極めて優れた効果
を有する。また、インドメタシン点眼剤と併用すること
によってさらに優れた当該作用、効果が得られる。
〔臨床例〕
アセチルザリチル酸−ＤＬ−リジン塩（Ａ Ｓ Ａ）の
術前、静脈内投与による白内障嚢外摘出術時の縮瞳抑制
効果につき検討した。
方法：術前の散瞳はミドリンＰ（登録商標）、ネオンネ
ジン（登録商標）点眼により行い、症例は次の５群に分
けられた。尚、各群２０眼とした。
■群：インドメタシン（ＩＭ）点眼（術前２時間、１時
間、３０分、３回）のみ
■群：ＡＳＡ９００ｍｇ静注（術前３０分、１回）のみ
■群：■Ｍ点眼＋ＡＳＡ９００ｍｇ静注（術前３０分、
１回）併用
■群：■Ｍ点眼＋ＡＳＡ９００ｍｇ静注（術前１時間、
１回）併用
Ｖ群：ＡＳＡ９００ｍｇ静注（術前１時間、１回）のみ
術前・術後の瞳孔径は顕微鏡下でカリバーにて測定した
。各群における術前・術後の瞳孔径の変化率は最小瞳孔
径を１ｍｍと仮定し、次式％式％
（式中、Ｐｏ は術前の瞳孔径を、Ｐｌは術後の瞳孔
径を示す。）
によって求め、その結果を第１図に示した。
ｌ ＩＩ、 １１１群に対し■、 Ｖ群はｐ＜０．０
１で有意差があり、■群とＶ群との間では有意差はなか
った。
結果と結論：
ＡＳＡの術前６０分の投与群の効果は、ＩＭ点眼群、Ａ
ＳＡの術前３０分の投与群および両者の併用群より、縮
瞳抑制効果が有意に大であった。ＡＳＡの術前６０分の
投与にＴＭ点眼を併用した群ではより強い縮瞳抑制効果
が得られた。また、金側に副作用を示すものはなかった
。これらの成績よりアセチルサリチル酸−ＤＬ−リジン
塩静注剤は白内障堂外摘出術中に生ずる縮瞳に対して、
インドメタシン点眼剤よりも優れた有用性が認められた
。
４、図面の簡単な説明
第１図は、本発明製剤を使用時の術前・術後の縮瞳径変
化率を示すためのグラフである。
第１図FIG. 1 is a graph showing the rate of change in pupil diameter before and after surgery when using the preparation of the present invention. :Q-2~已' No. 1 Procedural Amendment (Voluntary) February 19, 1985 1, Description of the case 1985 Patent Application No. 263092 2, Name of the invention Miosis inhibitor for eye surgery 3 , Relationship with the case of the person making the amendment Patent applicant name Midori Juji Co., Ltd. 4, agent ■541 Address 406 New Life Hirano-cho, 4-53-3 Hirano-cho, Higashi-ku, Osaka Telephone: (06) 227-1156 Column 6 of ``Detailed Description of the Invention'' in the Specification, Contents of Amendment (1) ``1000 mgJ to r
Corrected to 900mgJ. (September 18, 1985, Patent Application No. 263092, filed in 1985) Name of the invention: Miosis inhibitor for eye surgery 3, Relationship with the amended person's case Patent application Name of Person Midori Juji Co., Ltd. 4, Agent ■541 Address 406 New Life Hirano-cho, 4-53-3 Hirano-cho, Higashi-ku, Osaka (06) 227-1156 Full text and drawings. Description (correction) 1. Name of the invention An agent for suppressing miosis during eye surgery 2. Claims The active ingredient is at least one selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof. Miosis inhibitor during eye surgery. 3. Detailed Description of the Invention [Technical Field] The present invention relates to an agent for suppressing miosis during eye surgery, which contains at least one selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof as an active ingredient. [Background of the Invention] Acetylsalicylic acid has long been used as an analgesic, antipyretic, and antirheumatic drug, and in recent years has been widely used as a nonsteroidal anti-inflammatory drug to treat rheumatism, arthritis, neuralgia, muscle pain, etc. However, to date, the use of acetylsalicylic acid as a miotic inhibitor during eye surgery has not been known. Miosis at the time of eye 4+j is a troublesome problem that hinders surgery. Recently, indomethacin eye drops have been developed and used to prevent miosis during eye surgery, but there is a desire to develop a more effective drug. [Problems to be Solved by the Invention] An object of the present invention is to provide a miosis inhibitor for use in eye surgery that has a strong miosis inhibiting effect, can provide a reliable miosis inhibiting effect, and has fewer side effects. There is a particular thing. [Means for Solving the Problems] As a result of various studies to solve the above object, the present inventors have found that acetylsalicylic acid, its derivatives, and their physiologically acceptable salts have strong condensation properties. The present invention was completed by discovering that it has a pupil suppressing effect and confirming its safety. That is, the present invention provides a method for use in eye surgery that contains at least one type of active ingredient selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof (hereinafter collectively referred to as the active ingredient of the present invention). Concerning miotic inhibitors. Acetylsalicylic acid or its 5A used in the present invention
Examples of the salts of the sensitive body include organic base salts, alkali metal salts (such as I-IJum salts), and alkaline earth metal salts (such as calcium salts). Salts with basic amino acids (eg, arginine, lysine) are particularly preferred. Particularly preferred is a lysine salt of acetylsalicylic acid (particularly acetylsalicyl H=D L-lysine salt). Such salts are water soluble and can be administered locally to the eye or intravenously, and there is no risk of exacerbation of eye infections or steroid glaucoma, and they do not cause gastrointestinal disorders that are known from oral drugs. There is no trigger. There are no particular limitations on the derivative of acetylsalicylic acid as long as it suppresses miosis during eye surgery, and water-soluble ones are particularly preferred, either by themselves or in the form of a salt. The method for producing acetylsalicylic acid-DL-lysine salt is described in the specification of JP-A-56-10110. When the active ingredient of the present invention is used in combination with indomethacin eye drops, it exhibits even more excellent miosis suppressing action during eye surgery. The active ingredient of the present invention is usually administered several minutes to several hours before eye surgery.
It is administered orally, intravenously, or locally into the eye. The dosage may be appropriately selected depending on body weight, age, etc., and is usually about 5 to 50 mg/kg of acetylsalicylic acid. [Actions and Effects of the Invention] The miosis inhibitor during eye surgery of the present invention has a high inhibitory effect on miosis during eye surgery, as is clear from the clinical examples described later. It has extremely excellent effects as a miosis inhibitor. Moreover, even more excellent effects and effects can be obtained by using it in combination with indomethacin eye drops. [Clinical Example] The effect of preoperatively intravenously administering acetylsalicylic acid-DL-lysine salt (ASA) on miosis suppression during extracapsular cataract extraction was investigated. Method: Preoperative mydriasis was performed using Midrin P (registered trademark) and Neonnejin (registered trademark) eye drops, and the cases were divided into the following 5 groups. There were 20 eyes in each group. ■Group: Indomethacin (IM) eye drops (2 hours, 1 hour, 30 minutes, 3 times before surgery) only ■Group: ASA 900mg intravenous injection (1 time, 30 minutes before surgery) only ■Group: ■M eye drops + ASA 900mg intravenously ( 30 minutes before surgery
1 time) combination ■ Group: ■M eye drops + ASA 900mg intravenous injection (1 hour before surgery,
1 time) Combination group V: 900 mg of ASA intravenously injected (1 hour before surgery, 1 time) only The pupil diameter before and after surgery was measured with Calibur under a microscope. The rate of change in pupil diameter before and after surgery in each group is calculated using the following formula, assuming that the minimum pupil diameter is 1 mm. ), and the results are shown in Figure 1. l II, Group 111 vs. ■, Group V p<0.0
There was a significant difference in 1, and there was no significant difference between group ■ and group V. Results and Conclusions: The effect of the ASA administration group 60 minutes before surgery was greater than that of the IM eye drop group and A
The miosis suppressing effect was significantly greater than the SA administration group 30 minutes before surgery and the combination group. A stronger miosis suppressing effect was obtained in the group in which ASA was administered 60 minutes before surgery in combination with TM eye drops. Furthermore, there were no side effects on the gold side. These results show that intravenous acetylsalicylic acid-DL-lysine salt is effective against miosis that occurs during external cataract extraction.
It was found to be more useful than indomethacin eye drops. 4. Brief Description of the Drawings FIG. 1 is a graph showing the rate of change in miosis diameter before and after surgery when using the preparation of the present invention. Figure 1
Claims (1)
的に許容される塩から選ばれる少なくとも一種を有効成
分とする眼手術時の縮瞳抑制剤。A miotic inhibitor for eye surgery, which contains at least one selected from acetylsalicylic acid, derivatives thereof, and physiologically acceptable salts thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26309285A JPS62123119A (en) | 1985-11-22 | 1985-11-22 | Miotic inhibitor in ophthalmic operation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26309285A JPS62123119A (en) | 1985-11-22 | 1985-11-22 | Miotic inhibitor in ophthalmic operation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62123119A true JPS62123119A (en) | 1987-06-04 |
Family
ID=17384717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26309285A Pending JPS62123119A (en) | 1985-11-22 | 1985-11-22 | Miotic inhibitor in ophthalmic operation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62123119A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687673A1 (en) * | 1992-01-13 | 1993-08-27 | Jung Jean | AMINE SALTS OF ARYLCARBOXYLIC ACIDS, STERILIZABLE, WATER SOLUBLE, USED IN OPHTHALMOLOGY AND / OR IN THE OTORHINOLARYNGOLOGICAL SPHERE. |
| WO1995017178A1 (en) * | 1993-12-22 | 1995-06-29 | The Regents Of The University Of California | Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure |
| US5599535A (en) * | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
-
1985
- 1985-11-22 JP JP26309285A patent/JPS62123119A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687673A1 (en) * | 1992-01-13 | 1993-08-27 | Jung Jean | AMINE SALTS OF ARYLCARBOXYLIC ACIDS, STERILIZABLE, WATER SOLUBLE, USED IN OPHTHALMOLOGY AND / OR IN THE OTORHINOLARYNGOLOGICAL SPHERE. |
| WO1995017178A1 (en) * | 1993-12-22 | 1995-06-29 | The Regents Of The University Of California | Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure |
| US5474985A (en) * | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| US5599535A (en) * | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10617735B2 (en) | Methods and compositions for preserving retinal ganglion cells | |
| KR960005707B1 (en) | Pharmaceutical composition containing benzoylphenyl acetic acid derivatives | |
| AU754064B2 (en) | Anti-inflammatory eye drops | |
| JPH01104023A (en) | Preserving system for ophthalmic medicine | |
| JPS58126810A (en) | Ophthalmic anti-inflammatory solution and preparation thereof | |
| JPS62178514A (en) | Agent for lowering intraocular pressure | |
| WO2005030221A1 (en) | Therapeutic agent for ageing macular degeneration | |
| JPS60149521A (en) | Eye drop for remedy and prevention of hypertonia bulbi and glaucoma | |
| EP2114398A1 (en) | Isosorbide mononitrate derivatives for the treatment of ocular hypertension | |
| US20070105950A1 (en) | Treatment of ophthalmic disorders using urea and urea derivatives | |
| US5506241A (en) | Argatroban preparations for ophthalmic use | |
| JPS62123119A (en) | Miotic inhibitor in ophthalmic operation | |
| Lalonde et al. | Zidovudine-induced macular edema | |
| AU3149793A (en) | Pyridylguanidine compounds for treatment of erectile dysfunction | |
| AU668710B2 (en) | Argatroban preparations for ophthalmic use | |
| ES2361932T3 (en) | ANGIOGENESIS INHIBITOR CONTAINING AN AMINA DERIVATIVE AS ACTIVE INGREDIENT. | |
| IT9086204A1 (en) | METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE | |
| AU2003213084B2 (en) | Treatment of ophthalmic disorders using urea and urea derivatives | |
| JPS5929616A (en) | Anti-inflammatory ophthalmic solution and preparation thereof | |
| JPH06172176A (en) | Intraocular tension depressant with azimarin as essential ingredient | |
| KR900701324A (en) | Drugs for pathological vascular permeability and plasma loss to tissues | |
| JPS63502270A (en) | Ophthalmic pharmaceutical composition having mydriatic effect | |
| JPH10203979A (en) | Eye antiinflammatory agent containing tiaprofenic acid | |
| RU2214201C2 (en) | Method for treating edematic maculopathy | |
| Schulman et al. | Toxicity of intravitreal oxiconazole |